VSY Biotechnology GmbH is proud to announce its latest drug, TR-C 19 which has been developed for the treatment of COVID-19 patients by the R&D team of the VSY Biotechnology. Studies have revealed that this new drug can neutralize the coronavirus isolated in a laboratory. The drug is at the approval stage for testing on the voluntary coronavirus patients and clinical trials. Authorities have accelerated the evaluation of TR-C 19 considering the emergency conditions.
Chairman of the Board of Directors of VSY Biotechnology GmbH, Dr. Ercan Varlibas stated that VSY Biotechnology has completed many pioneering R&D projects by producing new technologies and credit goes to the innovation power and R&D team. The TR-C 19 project is one of the most important projects that the team has been developing. Voluntary and clinical trials will be arranged in collaboration with Turkey’s Health Sciences University (SBU). The initial results of voluntary trials on infected patients will be shared publicly in the coming weeks.
VSY Biotechnology is an innovation-driven company with its progressive R&D activities in orthopaedics, aesthetics, ophthalmology, and biotechnological drugs. VSY Biotechnology GmbH is focused on designing, developing and manufacturing superior state-of-the-art products to serve, patients, doctors and consumers beyond their expectations.
SBU Rector Cevdet Erdöl said Turkey has taken some important steps in the challenge to discover a cure for the novel coronavirus. He added that TR-C 19 is one such example ready to be tested on volunteers. It will soon be licensed. He said the collaboration between Turkey’s universities and the health care industry has become more significant than ever due to the COVID-19 pandemic.
Erdöl said that TR-C 19, which is also supported by the Health Ministry, neutralized the novel coronavirus that is previously isolated in the laboratory. The drug is ready to be tested on volunteer coronavirus patients. He added that they are waiting for the necessary approvals and planning to license TR-C 19 soon.
Ercan Varlıbaş said that the company is operating in 66 different countries and is utilizing all its potential to help struggle against the novel coronavirus pandemic. He said that VSY Biotechnology has done many development projects and groundbreaking research. The drug TR-C 19 against the novel coronavirus is one of its most significant projects. The level of cooperation with the SBU is an important factor in bringing this new drug to the implementation process in such a short time. Both Varlıbaş and Erdöl said developments regarding the TR-C 19 drug will be shared soon.
The Turkish state and private corporations have set up to develop coronavirus drugs and vaccines. The country has made huge investments to taken possible precautions against COVID-19 pandemics. One of the top scientific bodies in Turkey, TÜBİTAK, has invested TL 2.3 billion ($300 million) for developing 16 vaccine and other projects over the last five years. Moreover, there are 16 vaccine and medicine projects run by the “COVID-19 Turkey Platform,” which includes 225 researchers from 25 universities, 8 public research bodies and 8 private firms.
Turkey’s Yunus Emre Institute has also launched an online scientific hub to help experts working for the development of a vaccine for the novel coronavirus. The portal, covid19.tabipacademy.com, is a project of the TABİP, the Academic and Scientific Cooperation Project of Turkey. It is an online hub of science diplomacy which brings Turkish and other foreign researchers together for creating the national science inventory for the country. The newly made portal allows all partners who are working hard to find a cure for the novel coronavirus and allows professionals to follow the most up-to-date scientific studies and technological developments from reliable sources.